- Home
- AGIO vs WGS Comparison
AGIO vs WGS Comparison
Compare AGIO & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- WGS
- Stock Information
- Founded
- AGIO 2007
- WGS 2017
- Country
- AGIO United States
- WGS United States
- Employees
- AGIO N/A
- WGS N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- AGIO Health Care
- WGS Technology
- Exchange
- AGIO Nasdaq
- WGS Nasdaq
- Market Cap
- AGIO 2.3B
- WGS 2.4B
- IPO Year
- AGIO 2013
- WGS N/A
- Fundamental
- Price
- AGIO $36.78
- WGS $123.95
- Analyst Decision
- AGIO Buy
- WGS Strong Buy
- Analyst Count
- AGIO 6
- WGS 7
- Target Price
- AGIO $57.00
- WGS $102.14
- AVG Volume (30 Days)
- AGIO 779.8K
- WGS 613.1K
- Earning Date
- AGIO 10-30-2025
- WGS 10-28-2025
- Dividend Yield
- AGIO N/A
- WGS N/A
- EPS Growth
- AGIO N/A
- WGS N/A
- EPS
- AGIO 11.13
- WGS 0.05
- Revenue
- AGIO $40,875,000.00
- WGS $362,321,000.00
- Revenue This Year
- AGIO $28.19
- WGS $35.84
- Revenue Next Year
- AGIO $152.14
- WGS $18.46
- P/E Ratio
- AGIO $3.31
- WGS $2,532.45
- Revenue Growth
- AGIO 30.57
- WGS 48.70
- 52 Week Low
- AGIO $23.42
- WGS $34.95
- 52 Week High
- AGIO $62.58
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- AGIO 48.43
- WGS 55.07
- Support Level
- AGIO $34.97
- WGS $120.55
- Resistance Level
- AGIO $37.91
- WGS $129.25
- Average True Range (ATR)
- AGIO 1.67
- WGS 5.54
- MACD
- AGIO -0.21
- WGS -1.82
- Stochastic Oscillator
- AGIO 48.57
- WGS 22.01
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.